van Deelen G W, Huizing E H
ORL J Otorhinolaryngol Relat Spec. 1986;48(5):287-92. doi: 10.1159/000275884.
In 33 Menière patients (42 ears) the therapeutic effects of Dyazide (50 mg triamterene and 25 mg hydrochlorothiazide) were investigated in a cross-over placebo-controlled study. The hearing was measured by tone and speech audiometry whereas tinnitus and vertigo were recorded using fixed scales. In this study, Dyazide was found to have no significant effect on hearing or tinnitus. However, the vestibular complaints decreased significantly during the Dyazide treatment. Ears with a positive glycerol or furosemide test and ears with a fluctuating hearing loss did not show significant differences in hearing thresholds between the two periods in the trial. Of the 33 patients 17 had a distinct preference for Dyazide whereas 3 patients chose the placebo. The remaining 13 patients had no preference.
在一项交叉安慰剂对照研究中，对33例梅尼埃病患者（42耳）研究了双氢克尿噻（50毫克氨苯蝶啶和25毫克氢氯噻嗪）的治疗效果。通过纯音听力计和言语测听法测量听力，而耳鸣和眩晕则使用固定量表进行记录。在本研究中，发现双氢克尿噻对听力或耳鸣无显著影响。然而，在双氢克尿噻治疗期间，前庭症状明显减轻。甘油或速尿试验阳性的耳以及听力损失波动的耳在试验的两个阶段之间听力阈值没有显著差异。33例患者中，17例明显更喜欢双氢克尿噻，而3例患者选择了安慰剂。其余13例患者没有偏好。
